Acoustic Imaging keeps its identity
Ultrasound vendor Acoustic Imaging of Phoenix has abandoned plansannounced late last year to retire its name and corporate logoin favor of that of parent Dornier Medizintechnik (SCAN 11/22/95).The Acoustic Imaging marque will live on as part of
Ultrasound vendor Acoustic Imaging of Phoenix has abandoned plansannounced late last year to retire its name and corporate logoin favor of that of parent Dornier Medizintechnik (SCAN 11/22/95).The Acoustic Imaging marque will live on as part of Dornier'snew logo, which was released late last month.
Acoustic Imaging decided to keep its name after members ofthe ultrasound community said they opposed the change, accordingto Steven Kaska, worldwide director of marketing and marketingcommunications.
"We went out to some of our key physicians, and they allfelt it was a mistake to drop a 10-year identity," Kaskasaid. "We can't argue with that."
Dornier's new logo, a human-like figure with outstretched arms,replaces the four-point star used by former Dornier parent Daimler-BenzAerospace (DASA). DASA sold a majority interest in Dornier toSingapore Technologies in February (SCAN 2/28/96). Acoustic Imaging,Dornier Medical Systems, and other DMT companies will use thenew logo along with their own company names.
In other Acoustic Imaging news, the company has finalized anagreement with Fischer Imaging of Denver in which Fischer willmarket AI's Performa ultrasound scanner in conjunction with Fischer'sMammotest breast biopsy system (SCAN 6/5/96). AI will continueto sell Performa in stand-alone situations.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
